Taltz

Showing 7 posts of 7 posts found.

lilly_building_with_american_flag_web

Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

August 15, 2019
Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …

Eli Lilly’s Taltz shows superiority over AbbVie’s Humira

December 18, 2018
Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …

Lilly posts promising P3 Taltz data

February 14, 2018
Research and Development Cosentyx, Eli Lilly, IL-17, Novartis, Taltz, biotech, drugs, pharma, pharmaceutical

The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, …

lilly_entrance_web

Eli Lilly’s Taltz get EU approval in psoriatic arthritis subgroup

January 24, 2018
Research and Development, Sales and Marketing EU, Eli Lilly, Europe, European Commission, Taltz, pharma, psoriatic arthritis

Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission …

Lilly posts impressive psoriasis results in comparison study

March 6, 2017
Research and Development, Sales and Marketing J&J, JJ, Stelara, Taltz, lilly

Eli Lilly has revealed strong results in a study comparing its psoriasis treatment, Taltz (ixekizumab), to Johnson & Johnson’s Stelara. …

eli_lilly

FDA approves Lilly’s plaque psoriasis drug Taltz

March 23, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …

eli_lilly

CHMP recommends Lilly psoriasis drug for approval

February 29, 2016
Research and Development Eli Lilly, Taltz, psoriasis

Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Latest content